We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.
- Authors
Roumeliotou, Argyro; Strati, Areti; Chamchougia, Foteini; Xagara, Anastasia; Tserpeli, Victoria; Smilkou, Stavroula; Lagopodi, Elina; Christopoulou, Athina; Kontopodis, Emmanouil; Drositis, Ioannis; Androulakis, Nikolaos; Georgoulias, Vassilis; Koinis, Filippos; Kotsakis, Athanasios; Lianidou, Evi; Kallergi, Galatea
- Abstract
CXCR4, JUNB and PD-L1 are implicated in cancer progression and metastasis. The current study investigated these biomarkers in CTCs isolated from metastatic prostate cancer (mPCa) patients at the RNA and protein levels. CTCs were isolated from 48 mPCa patients using the Ficoll density gradient and ISET system (17 out of 48). The (CK/PD-L1/CD45) and (CK/CXCR4/JUNB) phenotypes were identified using two triple immunofluorescence stainings followed by VyCAP platform analysis. Molecular analysis was conducted with an EpCAM-dependent method for 25/48 patients. CK-8, CK-18, CK-19, JUNB, CXCR4, PD-L1, and B2M (reference gene) were analyzed with RT-qPCR. The (CK+/PD-L1+/CD45-) and the (CK+/CXCR4+/JUNB+) were the most frequent phenotypes (61.1% and 62.5%, respectively). Furthermore, the (CK+/CXCR4+/JUNB-) phenotype was correlated with poorer progression-free survival [(PFS), HR: 2.5, p = 0.049], while the (CK+/PD-L1+/CD45-) phenotype was linked to decreased overall survival [(OS), HR: 262.7, p = 0.007]. Molecular analysis revealed that 76.0% of the samples were positive for CK-8,18, and 19, while 28.0% were positive for JUNB, 44.0% for CXCR4, and 48.0% for PD-L1. Conclusively, CXCR4, JUNB, and PD-L1 were highly expressed in CTCs from mPCa patients. The CXCR4 protein expression was associated with poorer PFS, while PD-L1 was correlated with decreased OS, providing new biomarkers with potential clinical relevance.
- Subjects
PROSTATE cancer patients; CXCR4 receptors; PROGRAMMED death-ligand 1; OVERALL survival; BIOMARKERS
- Publication
Cells (2073-4409), 2024, Vol 13, Issue 9, p782
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells13090782